Chordia Therapeutics Inc. (TYO:190A)
Japan flag Japan · Delayed Price · Currency is JPY
50.00
0.00 (0.00%)
Oct 26, 2026, 3:30 PM JST

Chordia Therapeutics Financials Overview

Millions JPY. Fiscal year is Sep - Aug.

Revenue & Profits

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023
Period EndingAug '26 Aug '26 Aug '25 Aug '24 Aug '23
Revenue
----2,500
Revenue Growth
-----
Gross Profit
----2,500
Operating Income
-1,474-1,474-1,790-1,801212.06
Net Income
-1,455-1,455-1,786-1,827223.34
Earnings Per Share
-19.74-19.74-26.03-31.113.96
EPS Growth
-----

Cash & Debt

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023
Period EndingAug '26 Aug '26 Aug '25 Aug '24 Aug '23
Net Cash (Debt)
2,0522,0522,5494,3304,799
Net Cash Growth
-19.49%-19.49%-41.13%-9.78%-
Net Cash Per Share
27.8427.8437.1573.7285.02
Cash & Investments
2,0522,0522,5494,3304,799

Cash Flow & CapEx

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023
Period EndingAug '26 Aug '26 Aug '25 Aug '24 Aug '23
Operating Cash Flow
-1,419-1,419-1,837-1,937543.73
Capital Expenditures
-2.6-2.6-5.33-0.54-0.35
Free Cash Flow
-1,421-1,421-1,842-1,938543.38
Free Cash Flow Growth
-----

Margins

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023
Period EndingAug '26 Aug '26 Aug '25 Aug '24 Aug '23
Gross Margin
----100.00%
Operating Margin
----8.48%
Pretax Margin
----9.03%
Profit Margin
----8.93%
FCF Margin
----21.73%

Valuation

Selected indicators aren't available for this stock.